Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


ChemoCentryx announces approval in Japan of Tavneos for the treatment of ANCA-associated vasculitis

Written by | 26 Dec 2021

ChemoCentryx, Inc., announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market Tavneos™ (avacopan), an orally administered… read more.

FDA approves Tavneos for vasculitis – ChemoCentryx

Written by | 16 Oct 2021

ChemoCentryx announced that the FDA has approved Tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.